인플루엔자 백신 시장 : 백신 유형별, 연령층별, 투여량별, 제형별, 유통 경로별, 최종 사용자별 시장 예측(2026-2032년)

The Influenza Vaccine Market is projected to grow by USD 17.94 billion at a CAGR of 9.65% by 2032.

Influenza Vaccine Market Overview

Influenza vaccination remains one of the most widely used public health interventions for reducing seasonal respiratory disease burden, hospitalizations, and preventable deaths. The World Health Organization (WHO) estimates that seasonal influenza causes approximately 1 billion infections, 3 million to 5 million severe cases, and 290,000 to 650,000 respiratory deaths globally each year, making annual immunization a persistent priority for health systems, employers, payers, and vaccine manufacturers.

The influenza vaccine landscape is shaped by recurring demand, evolving viral strains, government procurement, and the need for timely production ahead of each flu season. Because influenza viruses undergo frequent antigenic drift, WHO convenes twice yearly to recommend vaccine composition for the Northern and Southern Hemisphere influenza seasons. This creates a uniquely cyclical market in which strain surveillance, manufacturing speed, cold-chain readiness, and public confidence directly influence vaccine availability and uptake.

Growth opportunities are strongest where influenza immunization programs are expanding beyond high-risk groups to broader adult, pediatric, workplace, pharmacy-based, and community access models. At the same time, the industry is moving from traditional egg-based manufacturing toward cell-based influenza vaccines, recombinant influenza vaccines, adjuvanted vaccines, high-dose flu vaccines, and next-generation platforms designed to improve effectiveness, scalability, and resilience against strain mismatch.

Transformative Shifts in the Influenza Vaccine Landscape

The influenza vaccine industry is undergoing a structural shift from seasonal supply planning to more adaptive, technology-enabled immunization strategies. Egg-based vaccines continue to serve as a major global supply backbone, but cell-based and recombinant vaccines are gaining relevance because they can reduce egg-adaptation concerns and support faster production workflows. High-dose and adjuvanted formulations are also increasingly important for older adults, who experience higher risks of severe influenza outcomes.

Access channels are changing as well. In the United States and several other mature markets, pharmacies, retail clinics, employer programs, and digital appointment systems have made influenza vaccination more convenient. In Europe, national immunization programs continue to prioritize older adults, pregnant individuals, healthcare workers, and people with chronic conditions, while policy emphasis is growing around improving coverage after pandemic-era disruptions.

The competitive landscape is also being reshaped by lessons from COVID-19 vaccine deployment. Governments and manufacturers are placing greater emphasis on supply security, regional manufacturing capacity, real-world evidence, and public communication. These changes are increasing demand for flexible production platforms, reliable pharmacovigilance, and evidence-based outreach that addresses vaccine hesitancy, misinformation, and uneven access across population groups.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler across influenza vaccine research, surveillance, production planning, and commercialization. AI-assisted analysis of genomic surveillance data can help researchers identify emerging variants, monitor antigenic drift, and prioritize strains for further laboratory assessment. While vaccine strain selection remains a scientific and regulatory process led by global influenza surveillance networks and expert committees, AI can improve the speed and scale of evidence synthesis.

AI is also supporting clinical development and real-world evidence generation. Machine learning can assist in trial site selection, population stratification, safety signal detection, and post-marketing effectiveness analysis using large healthcare datasets. These capabilities are particularly important for influenza vaccines because effectiveness varies by season, age group, circulating strain, and vaccine platform.

Commercially, AI can improve demand forecasting, inventory allocation, and outreach timing. Health systems, pharmacies, and public health agencies can use predictive analytics to identify communities with historically low vaccination rates, optimize appointment capacity, reduce wastage, and refine communication windows before peak influenza activity. The cumulative impact is not the replacement of established scientific oversight, but a more responsive influenza vaccine ecosystem with better surveillance intelligence, more efficient operations, and more targeted public health engagement.

Key Regional Insights

Asia-Pacific is one of the most dynamic influenza vaccine regions due to large population bases, rising healthcare investment, and government-led immunization expansion. China, India, Japan, South Korea, and Australia each play distinct roles, ranging from large-scale domestic production and pediatric immunization demand to mature seasonal vaccination programs and advanced disease surveillance. The region's tropical and subtropical climates also create complex influenza seasonality, requiring flexible surveillance, localized campaign timing, and sustained public health communication.

North America remains highly developed for seasonal flu vaccine access, supported by strong annual recommendations, broad pharmacy delivery, employer-sponsored vaccination, and established reimbursement systems. The U.S. Centers for Disease Control and Prevention recommends annual influenza vaccination for everyone aged 6 months and older, creating a stable policy foundation for recurring immunization. Canada similarly supports seasonal influenza vaccination through provincial and territorial programs that prioritize risk groups while enabling broader community access.

Latin America is advancing through public-sector procurement, national immunization campaigns, and increasing attention to adult, pediatric, and maternal vaccination. Brazil and Mexico are central demand anchors because of their large public health systems and recurring seasonal campaigns, while other countries continue strengthening coverage among older adults, children, healthcare workers, pregnant individuals, and people with chronic disease.

Europe benefits from mature regulatory oversight, national immunization technical advisory groups, and strong public health infrastructure. The European Union emphasizes vaccine safety monitoring, coordinated disease surveillance, and improved coverage among older adults and medical risk groups. The Middle East is supported by GCC healthcare modernization, travel medicine needs, pilgrimage-related preventive health planning, and growing investment in preventive care. Africa remains a critical access region where influenza vaccination is concentrated in priority groups and constrained by financing, awareness, healthcare workforce capacity, and cold-chain infrastructure, even as surveillance improvements strengthen the evidence base for influenza immunization programs.

Key Group Insights

ASEAN presents meaningful growth potential as member states strengthen disease surveillance, expand primary care, and improve access to seasonal immunization in urban and semi-urban populations. Influenza seasonality across Southeast Asia can vary substantially, making localized epidemiology, flexible procurement, and campaign design essential for improving vaccine uptake and protecting high-risk groups.

The GCC is characterized by relatively advanced healthcare infrastructure, high inbound and outbound travel, and strong government capacity to implement preventive health campaigns. Influenza vaccination is particularly relevant for healthcare workers, people with chronic conditions, older adults, and pilgrims or travelers moving through major regional hubs, where respiratory disease prevention supports both population health and health system readiness.

The European Union provides a coordinated regulatory and surveillance environment while allowing country-level immunization strategies. EU priorities include increasing coverage in older adults and medical risk groups, supporting pharmacovigilance, improving cross-border disease intelligence, and sustaining public trust through transparent vaccine safety communication.

BRICS countries collectively represent a major share of global population and future vaccine demand. Brazil, Russia, India, China, and South Africa combine large public health needs with growing domestic manufacturing capabilities and policy interest in vaccine security. G7 countries remain influential through advanced R&D ecosystems, premium vaccine adoption, funding capacity, and global health partnerships. NATO member countries are also relevant because military readiness, healthcare worker protection, emergency preparedness, and resilient medical supply chains reinforce the strategic value of reliable influenza vaccine supply.

Key Country Insights

The United States is a leading market for influenza vaccines due to universal annual vaccination recommendations, extensive pharmacy delivery, employer programs, and strong uptake among older adults. Canada maintains broad public funding through provincial and territorial programs, while Mexico relies on national campaigns that prioritize children, older adults, pregnant individuals, healthcare workers, and people with chronic conditions. Brazil has one of Latin America's largest public immunization infrastructures and uses seasonal campaigns to reach priority groups at scale, supported by established public-sector vaccine delivery experience.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature influenza vaccination programs supported by national guidance and public reimbursement for eligible groups. The United Kingdom has expanded convenient access through general practice and pharmacy channels, while Germany and France emphasize risk-based recommendations, medical professional engagement, and coverage improvement. Italy and Spain remain important markets due to aging populations and recurring public health campaigns focused on older adults and vulnerable groups. Russia combines domestic vaccine production capacity with national immunization priorities across risk groups and public health institutions.

In Asia-Pacific, China and India represent large long-term opportunities because of population scale, expanding healthcare access, local manufacturing capability, and growing awareness of adult immunization. Japan is a mature market with strong demand among older adults and established seasonal vaccination practices. Australia's Southern Hemisphere influenza season provides important epidemiological intelligence for global strain monitoring and vaccine composition discussions, while South Korea combines advanced healthcare infrastructure with strong domestic biotechnology capability and seasonal immunization programs that support high-risk populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platform diversification to balance cost, scale, and performance. Egg-based manufacturing will remain important, but investment in cell-based, recombinant, adjuvanted, high-dose, and potentially mRNA-based influenza vaccines can improve resilience against strain mismatch and supply disruption.

Manufacturers and healthcare stakeholders should strengthen real-world evidence capabilities by tracking vaccine effectiveness by age, risk group, strain, and platform. This evidence is essential for payer engagement, public trust, clinical guideline support, and differentiated product positioning in competitive tenders and national immunization programs.

Commercial teams should expand access through pharmacies, workplaces, schools where permitted, digital scheduling, mobile clinics, and targeted reminders. Public health partners should focus messaging on high-risk groups, including older adults, pregnant individuals, young children, healthcare workers, and people with chronic conditions. Across emerging markets, partnerships that improve cold-chain capacity, healthcare worker training, financing pathways, and local surveillance can unlock sustainable demand while strengthening influenza preparedness.

Research Methodology

This executive summary is developed using a structured secondary research methodology grounded in authoritative public health, regulatory, and scientific sources. Core inputs include WHO influenza burden estimates and strain-selection processes, CDC vaccination recommendations, European public health guidance, national immunization policies, regulatory information from agencies such as the FDA and EMA, and peer-reviewed evidence on vaccine effectiveness, manufacturing platforms, and influenza epidemiology.

The analysis triangulates epidemiological burden, immunization policy, access channels, technology trends, and regional healthcare infrastructure. It avoids unsupported market sizing claims and focuses on verifiable drivers such as annual vaccination recommendations, demographic risk, surveillance systems, platform innovation, procurement dynamics, safety monitoring, and government-led prevention priorities.

Insights are organized to support executive decision-making across strategy, market access, product planning, and regional prioritization. All content is written in original language for web publication and optimized around industry-relevant terms including influenza vaccine market, seasonal flu vaccine, recombinant influenza vaccine, cell-based influenza vaccine, high-dose flu vaccine, flu shot, and influenza immunization programs.

Conclusion

The influenza vaccine market is defined by recurring global need, evolving viral epidemiology, and rising expectations for faster, more effective, and more accessible immunization. Annual vaccination will remain central to public health policy because influenza continues to cause substantial severe disease and mortality worldwide, particularly among older adults, young children, pregnant individuals, healthcare workers, and people with underlying medical conditions.

The next phase of industry advancement will be driven by improved vaccine platforms, stronger surveillance, AI-enabled forecasting and operations, broader retail and community access, and targeted communication that addresses hesitancy. Organizations that combine scientific credibility, manufacturing flexibility, regional partnerships, and real-world evidence will be best positioned to compete in this essential segment of preventive healthcare.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Influenza Vaccine Market, by Vaccine Type

• 7.1. Inactivated
• 7.2. Live Attenuated
• 7.3. Recombinant

8. Influenza Vaccine Market, by Age Group

• 8.1. Adult
• 8.2. Geriatric
• 8.3. Pediatric

9. Influenza Vaccine Market, by Dosage

• 9.1. Multi Dose
• 9.2. Single Dose

10. Influenza Vaccine Market, by Presentation

• 10.1. Prefilled Syringe
  • 10.1.1. Glass Prefilled Syringe
  • 10.1.2. Plastic Prefilled Syringe
• 10.2. Vial
  • 10.2.1. Multi Dose Vial
  • 10.2.2. Single Dose Vial

11. Influenza Vaccine Market, by Distribution Channel

• 11.1. Direct Sales
• 11.2. Hospital Pharmacies

12. Influenza Vaccine Market, by End User

• 12.1. Clinics
  • 12.1.1. Outpatient Clinics
  • 12.1.2. Specialty Clinics
• 12.2. Hospitals
  • 12.2.1. Private Hospitals
  • 12.2.2. Public Hospitals

13. Influenza Vaccine Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Influenza Vaccine Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Influenza Vaccine Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Adimmune Corporation
• 17.3. Altimmune, Inc.
• 17.4. AstraZeneca plc
• 17.5. Bharat Biotech International Limited
• 17.6. BIKEN Co., Ltd.
• 17.7. BioDiem Ltd.
• 17.8. Changchun BCHT Biotechnology Co.
• 17.9. CSL Limited
• 17.10. Daiichi Sankyo Company, Limited
• 17.11. FluGen, Inc.
• 17.12. GlaxoSmithKline plc
• 17.13. Hualan Biological Engineering Inc.
• 17.14. Merck & Co., Inc.
• 17.15. Mitsubishi Tanabe Pharma Corporation
• 17.16. Moderna, Inc.
• 17.17. Novavax, Inc.
• 17.18. Pfizer Inc.
• 17.19. Sanofi
• 17.20. Seqirus Pty Ltd
• 17.21. Serum Institute of India Pvt. Ltd.
• 17.22. Sinovac Biotech Ltd.
• 17.23. SK bioscience Co., Ltd.
• 17.24. Valneva SE
• 17.25. Viatris Inc.